Should prenatal chromosomal microarray analysis be offered for isolated fetal growth restriction? A French multicenter study - 27/11/21
, Aline Receveur, MD c, Véronique Houfflin-Debarge, MD, PhD d, Valérie Goua, MD e, Vanina Castaigne, MD f, Jean-Marie Jouannic, MD, PhD g, Eve Mousty, MD h, Anne-Hélène Saliou, MD i, Hanane Bouchghoul, MD j, Thierry Rousseau, MD k, Anne-Sylvie Valat, MD l, Marion Groussolles, MD m, Florent Fuchs, MD, PhD n, Guillaume Benoist, MD, PhD o, Sophie Degre, MD p, Jérôme Massardier, MD q, Vassilis Tsatsaris, MD, PhD r, Pascale Kleinfinger, MD s, Jennifer Zeitlin, MA, DSc a, Alexandra Benachi, MD, PhD bOn behalf of the
French Federation of Fetal Medicine Centers
Abstract |
Background |
Compared with standard karyotype, chromosomal microarray analysis improves the detection of genetic anomalies and is thus recommended in many prenatal indications. However, evidence is still lacking on the clinical utility of chromosomal microarray analysis in cases of isolated fetal growth restriction.
Objective |
This study aimed to estimate the proportion of copy number variants detected by chromosomal microarray analysis and the incremental yield of chromosomal microarray analysis compared with karyotype in the detection of genetic abnormalities in fetuses with isolated fetal growth restriction.
Study Design |
This retrospective study included all singleton fetuses diagnosed with fetal growth restriction and no structural ultrasound anomalies and referred to 13 French fetal medicine centers over 1 year in 2016. Fetal growth restriction was defined as an estimated fetal weight of <tenth percentile for gestational age identified in ultrasound reports. For this analysis, we selected fetuses who underwent invasive genetic testing with karyotype and chromosomal microarray analysis results. Data were obtained from medical records and ultrasound databases and postmortem and placental examination reports in case of spontaneous stillbirths and terminations of pregnancy. Following the American College of Medical Genetics and Genomics guidelines, copy number variants were classified into 5 groups as following: pathogenic, likely pathogenic, variant of unknown significance, likely benign, and benign.
Results |
Of 682 referred fetuses diagnosed with isolated fetal growth restriction, both karyotype and chromosomal microarray analysis were performed in 146 fetuses. Overall, the detection rate of genetic anomalies found by chromosomal microarray analysis was estimated to be 7.5% (11 of 146 [95% confidence interval, 3.3–11.8]), including 10 copy number variants classified as pathogenic and 1 copy number variant classified as likely pathogenic. Among the 139 fetuses with normal karyotype, 5 were detected with pathogenic and likely pathogenic copy number variants, resulting in an incremental yield of 3.6% (95% confidence interval, 0.5–6.6) in chromosomal microarray analysis compared with karyotype. All fetuses detected with pathogenic or likely pathogenic copy number variants resulted in terminations of pregnancy. In addition, 3 fetuses with normal karyotype were detected with a variant of unknown significance (2.1%). Among the 7 fetuses with abnormal karyotype, chromosomal microarray analysis did not detect trisomy 18 mosaicism in all fetuses.
Conclusion |
Our study found that compared with karyotype, chromosomal microarray analysis improves the detection of genetic anomalies in fetuses diagnosed with isolated fetal growth restriction. These results support the use of chromosomal microarray analysis in addition to karyotype for isolated fetal growth restriction.
Le texte complet de cet article est disponible en PDF.Key words : chromosomal microarray, copy number variants, karyotype, fetal growth restriction, prenatal diagnosis
Plan
| The authors report no conflict of interest. |
|
| This study was supported by grants from the Agence de la Biomédecine (ABM). |
|
| Cite this article as: Monier I, Receveur A, Houfflin-Debarge V, et al. Should prenatal chromosomal microarray analysis be offered for isolated fetal growth restriction? A French multicenter study. Am J Obstet Gynecol 2021;225:676.e1-15. |
Vol 225 - N° 6
P. 676.e1-676.e15 - décembre 2021 Retour au numéro
Article précédent
- Dynamic esophageal patency assessment: an effective method for prenatally diagnosing esophageal atresia
- Eran Kassif, Tal Elkan Miller, Abraham Tsur, Yana Trozky, Tomer Gur, Hila De Castro, Efrat Hadi, Vered Yulzari, Alina Weissmann-Brenner, Baruch Messing, Rakefet Yoeli-Ullman, Roni Sharon, Shali Mazaki-Tovi, Reuven Achiron, Boaz Weisz, Tal Weissbach
- Experience of 300 cases of prenatal fetoscopic open spina bifida repair: report of the International Fetoscopic Neural Tube Defect Repair Consortium
- Magdalena Sanz Cortes, Ramen H. Chmait, Denise A. Lapa, Michael A. Belfort, Elena Carreras, Jena L. Miller, Robert Brawura Biskupski Samaha, Gerardo Sepulveda Gonzalez, Yuval Gielchinsky, Masami Yamamoto, Nicola Persico, Marta Santorum, Lucas Otaño, Ermos Nicolaou, Yoav Yinon, Fernanda Faig-Leite, Reynaldo Brandt, William Whitehead, Nerea Maiz, Ahmet Baschat, Przemyslaw Kosinski, Adriana Nieto-Sanjuanero, Jason Chu, Amir Kershenovich, Kypros H. Nicolaides
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?